Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Boehringer Ingelheim
McKesson
AstraZeneca
US Department of Justice
Medtronic
Novartis
Chubb
QuintilesIMS
Fuji

Generated: December 12, 2017

DrugPatentWatch Database Preview

Rhodes Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for RHODES PHARMS, and when can generic versions of RHODES PHARMS drugs launch?

RHODES PHARMS has fifteen approved drugs.

There are seven US patents protecting RHODES PHARMS drugs and there have been four Paragraph IV challenges on RHODES PHARMS drugs in the past three years.

There are forty-four patent family members on RHODES PHARMS drugs in fifteen countries and one supplementary protection certificate in one country.

Summary for Rhodes Pharms

International Patents:44
US Patents:7
Tradenames:10
Ingredients:9
NDAs:15
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Rhodes PharmsFENOFIBRATE (MICRONIZED)fenofibrateCAPSULE;ORAL075753-002Apr 9, 2002ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Rhodes PharmsAPTENSIO XRmethylphenidate hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL205831-001Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Rhodes PharmsAPTENSIO XRmethylphenidate hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL205831-004Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Rhodes PharmsAPTENSIO XRmethylphenidate hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL205831-007Apr 17, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Rhodes PharmsOXYCODONE HYDROCHLORIDEoxycodone hydrochlorideTABLET;ORAL091490-003Mar 9, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Rhodes PharmsMORPHINE SULFATEmorphine sulfateSOLUTION;ORAL206420-001Jul 12, 2016AARXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Rhodes PharmsAPTENSIO XRmethylphenidate hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL205831-005Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Rhodes PharmsAPTENSIO XRmethylphenidate hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL205831-001Apr 17, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Rhodes PharmsBUPRENORPHINE HYDROCHLORIDEbuprenorphine hydrochlorideTABLET;SUBLINGUAL207276-001Mar 27, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Rhodes PharmsAPTENSIO XRmethylphenidate hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL205831-007Apr 17, 2015RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for RHODES PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
methylphenidate hydrochlorideExtended-release Capsules30 mgAPTENSIO XR3/28/2016
methylphenidate hydrochlorideExtended-release Capsules15 mg, 20 mg, 40 mg and 50 mgAPTENSIO XR12/28/2015
methylphenidate hydrochlorideExtended-release Capsules10 mgAPTENSIO XR12/24/2015
methylphenidate hydrochlorideExtended-release Capsules60 mgAPTENSIO XR12/23/2015
hydromorphone hydrochlorideTablets2 mg, 4 mg, and 8 mgDILAUDID8/5/2013
hydromorphone hydrochlorideInjection2 mg/mLDILAUDID6/22/2011
hydromorphone hydrochlorideOral Solution5 mg/5mLDILAUDID2/25/2011

Non-Orange Book Patents for Rhodes Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis► Subscribe
6,673,367 Controlled/modified release oral methylphenidate formulations► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Rhodes Pharms Drugs

Country Document Number Estimated Expiration
Canada2854796► Subscribe
Cyprus1117845► Subscribe
Spain2309001► Subscribe
Australia2122700► Subscribe
Denmark1140088► Subscribe
Canada2355854► Subscribe
European Patent Office2003134► Subscribe
European Patent Office2338891► Subscribe
Canada2355644► Subscribe
Portugal1143937► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Rhodes Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Chinese Patent Office
Farmers Insurance
Johnson and Johnson
Cerilliant
Healthtrust
Julphar
Colorcon
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot